Search results
Showing 3061 to 3075 of 9065 results
Weight management: BMI recording (long term conditions) (IND320)
This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, at high risk of developing type 2 diabetes, hypertension, peripheral arterial disease, heart failure, COPD, dyslipidaemia, learning disability, obstructive sleep apnoea, schizophrenia, bipolar disorder or other psychoses who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with a diagnosis of heart failure on or after 1 April 2026 who have a recorded ejection fraction category (reduced, mildly reduced, or preserved). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the the percentage of patients with a current diagnosis of heart failure with reduced ejection fraction, who are currently treated with an angiotensin-converting enzyme inhibitor or angiotensin receptor-neprilysin inhibitor or angiotensin II receptor blocker, a beta blocker, a mineralocorticoid receptor antagonist and a sodium glucose co-transporter-2 inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with asthma on the register aged 12 years or over with a risk factor for poor outcomes who are prescribed maintenance and reliever therapy (MART) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with asthma on the register with a risk factor for poor outcomes, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
NICE has reviewed DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations. We think the guideline from DMD Care UK is a useful resource that will help clinicians improve care in this area
DMD Care UK's guideline on respiratory care: NICE review (NR2)
NICE has reviewed DMD Care UK’s guideline on respiratory care for Duchenne muscular dystrophy. We think the guideline from DMD Care UK is a useful resource that will help healthcare professionals improve care in this area
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
View recommendations for AMR1Show all sections
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Details of the business expenses incurred by the board and senior management team in delivery of their duties.
IMI and H2020 Grant funded projects with NICE
Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Agenda and papers of the NICE public board meeting on 10 December 2025
Agenda and papers of the NICE public board meeting on 19 March 2025